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Mental disorders affect a substantial proportion of our society and the importance of mental 
health became an even hotter topic after the Covid-19 pandemic resulted in social isolation. 
For most national health care systems, being understaffed and underfinanced are key defining 
characteristics. Pharmaceuticals tend to be overprescribed and in depth face-to-face cognitive-
behavioural therapy remains reserved mostly for those able to afford it. Alpha-Stim® medical 
technology is an innovative approach recognized by the American and British national health 
services alike. Thus, a cost analysis was performed to assess if a nationwide implementation 
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PRIMER ON PSYCHIATRIC EPIDEMIOLOGY 
In the European Union (EU), mental disorders affect 38% of the population (Wittchen et al. 
2011a). Depression is the largest cause of disability worldwide and its burden has been 
increasing (Vos et al. 2016; WHO 2017; UN 2017). Generalized anxiety disorder is also 
highly impairing (R. Lieb, Becker, and Altamura 2005). 
At any given moment, depression affects 7% to 12%  of the adult population, whereas 
lifetime prevalence is estimated to be between 11% and 18% (Bromet et al. 2011; Lim et al. 
2018; Wittchen et al. 2011a). 
The existing estimates of point prevalence of anxiety disorders vary between 14% and 41% of 
adult population (Guo et al. 2016; Munir, Zafar Gondal, and Takov 2017; Remes et al. 2016; 
Wittchen et al. 2011a). Among those above 82 years of age, the estimates are somewhat 
lower, going from 7% to 17% (Leray et al. 2011; Rezapour et al. 2020; Welzel et al. 2019). 
While its one-year prevalence is 9% (Watterson et al. 2017), the lifetime prevalence of 
anxiety disorders is between 5% and 9% (Kessler et al. 2011; Ruscio et al. 2017; Watterson et 
al. 2017). 
For comparison, during the Covid-19 outbreak, the prevalence of general anxiety disorders, 
depressive symptoms and insomnia in the Chinese adult population were 35%, 20%, and 
18%, respectively (Gao et al. 2020; Huang and Zhao 2020). In addition, 54% of Chinese 
respondents rated the psychological impact of the Covid-19 outbreak as moderate or severe; 
29% reported moderate to severe anxiety symptoms; and 17% reported moderate to severe 
depressive symptoms (Wang et al. 2020). The Americans were most concerned about facing 
increased anxiety (41%), more than about insolvency or reduced job security (UOPX 2020). 
Even in high-income countries, nearly 50% of people who suffer from mental disorders do 
not get treated (WHO 2012). For example, despite Singapore ranking as 9th on the 2019 
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Human Development Index (HDI), 62% of Singaporeans with anxiety disorders had not 
sought help after one year (Chang et al. 2019). Globally, the vast majority of patients is seen 
only in primary care and most treatments are often inadequate in relation to minimal standards 
published in treatment guidelines (Wittchen et al. 2011b). In general, the obstacles to mental 
health include lack of appropriate responses from health systems, such as lack of 
psychologists/psychiatrists or barriers in access to mental health care as well as lack of 
awareness and social stigma.  
This study considers a new medical technology for the treatment of mental disorders, Alpha 
Stim, which has the potential of addressing some of those obstacles. I focus on Slovenia, a 
country with significant shortage of clinical psychologists/psychiatrist, high regional 
differences in accessibility and increasing demand for psychiatric services. 
1ST LINE TREATMENT FOR MENTAL DISORDERS: PSYCHOTROPIC DRUGS  
Antidepressants (SSRIs) 
The average clinical response rate to antidepressants is around 50% (i.e. 50% reduction in 
symptomatology) (IQWiG 2017). While the efficacy measured during clinical trials is one of 
the most influential measures in treatment assessment, its external validity may be 
jeopardized by non-adherence to medication in real life (Pedersini and Kuehl 2014). The most 
comprehensive review of clinical trials found that all SSRIs were more effective than placebo, 
with relatively low odds ratios, between 2.1 and 1.4. Most of them were also associated with 
more dropouts than placebo. Only 18% of the trials included in this review were rated as low 
risk of bias (Cipriani et al. 2018). The English National Health Service (NHS) responded to 
this study, explaining that SSRIs are not highly effective; only more effective when compared 
to placebo (NHS 2018). An older paper with 3,500 citations reports only 37% response rate 
for monotherapy, no better than placebo (Rush et al. 2006; Santarsieri and Schwartz 2015). 
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Even though SSRIs might have statistically significant effects on depressive symptoms,  
trials often have high risk of bias and the clinical significance (outside the context of the trial) 
seems questionable (Procopio 2005). In addition, many trials and meta-analyses of SSRIs are 
authored by or linked to the industry and almost never report any caveats about SSRIs in their 
abstracts. Ebrahim et al. (2016) found that 29% of meta-analyses’ authors were employees of 
the drug manufacturer and 79% had at least some industry link. The meta-analyses including 
an employee of the manufacturer were 22 times less likely to have any criticism on the drug. 
Often there is misclassification, misrepresentation and under-reporting of serious harm, which 
means that we cannot be confident about the risk-benefit ratio of the drugs (Moncrieff 2016).  
In Denmark, the most frequent calls to the national medical advice hotline were inquiries 
relating to SSRIs withdrawal phenomena (Geffen et al. 2007). The current UK and USA 
Guidelines underestimate the severity and the duration of SSRIs withdrawal with significant 
clinical implications, as 56% of people experience withdrawal effects upon attempting to quit 
SSRIs, with 46% of people describing them as severe and often lasting for several weeks or 
months (Davies and Read 2019). The Royal College of Psychiatrists has since changed its 
guidelines accordingly (Council For Evidence-Based Psychiatry 2018; 2019).  
The withdrawal effects include sexual problems (72%), weight gain (65%) and adverse 
emotional effects, such as feeling emotionally numb (65%) and addicted (43%) (Cartwright et 
al. 2016). Other side effects include stroke, falls and fractures, epileptic seizures in the 
elderly, diabetes, deep vein thrombosis, gastrointestinal and intracranial bleeding (Kirsch 
2019). “Brain zaps” are another underappreciated symptom (Papp and Onton 2018). Lastly in 
children and adolescents, there appears to be an increased risk of suicidality and aggression 
(Sharma et al. 2016; Spielmans, Spence-Sing, and Parry 2020).  
In summary, SSRIs significantly increase the risk of both serious and non-serious adverse 
events (Jakobsen et al. 2017). Their benefits seem to be minimal, possibly without any 
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importance to the average patient with a major depressive disorder, and thus should not be 
used for adults with major depressive disorders before valid evidence has shown that the 
potential beneficial effects outweigh the harmful effects (Jakobsen, Gluud, and Kirsch 2019). 
The National Alliance of Mental Illness, the main funder of which is Pharma, lobbied for 
legalization of certain medicines (Harris 2009)and also disputed the ‘black box’ warnings on 
SSRIs causing suicide (CCHR International 2009; Harris 2009). Even the WHO had to 
officially retract its controversial guidelines on the use of opioid analgesics after accepting 
that the industry had an influence (Dyer 2020). A global team of influential researchers, 
clinicians and regulators are calling for trustworthy evidence and breaking ties with 
pharmaceutical companies not just on research but also on practice guidelines and education 
(Moynihan et al. 2019; Spilde, Bergstrøm, and Bazilchuk 2020).  
Anxiolytics 
While long term benzodiazepines (BZDs) use is not endorsed in the treatment guidelines 
for anxiety disorder, it is prevalent in real-world clinical settings. There is no evidence of a 
significant difference in response compared to placebo (Shinfuku et al. 2019). One study 
reports that 83% of patients were still anxious after the third month of treatment with BZDs 
(Barthelmé and Poirot 2008). Without strong evidence of efficacy and with significant 
evidence of risks, a variety of evidence-based treatments should be considered prior to 
initiating BZDs (Fluyau, Revadigar, and Manobianco 2018; Guina and Merrill 2018; Lader 
2008). There is significant concern regarding overprescribing of BZDs and the resulting 
harms (Brett and Murnion 2015; Weaver 2015). Despite all this, pharmacotherapy abuse may 
occur because we are treating mental health problems almost exclusively with drugs, with 
90% of patients staying in primary care. (Ávila 2015). With the current pandemic, anti-
anxiety medication prescriptions are up 34% and SSRIs prescriptions are up 19% in the US 
(Express Scripts 2020). 
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2nd LINE TREATMENT FOR MENTAL DISORDERS: iCBT 
Individual cognitive-behavioural therapy (iCBT) for the treatment of mental disorders can 
include 1 to 20 session of 30 to 120 min (Li et al. 2014; Laird et al. 2017). The standard is 8 
to 10 60-minute sessions (Morriss et al. 2019; Psychiatric Association of Slovenia 2017). 
Although the evidence-base of CBT is enormous, almost 80% of meta-analyses statistically 
significantly favour psychotherapy, and only 7% to 22% provided convincing evidence 
without biases. Furthermore, studies demonstrate small to moderate effects when compared to 
more conservative control groups, such as care-as-usual and pill placebo (Cuijpers et al. 2018; 
Dragioti et al. 2017; Hofmann et al. 2012). Furthermore, therapy experiences are associated 
with significant increases in undesirable traits and markers (e.g. chronic stress, depression, 
neuroticism) and significant decreases in desirable traits (e.g. self-esteem, conscientiousness) 
(Chow et al. 2017). In addition, conflicts of interest were confirmed in a systemic review (K. 
Lieb et al. 2016). Since it is still unknown whether therapies work through common or 
specific factors, it can be regarded as highly unstandardized (Cuijpers, Reijnders, and Huibers 
2019). While it may be effective, the evidence is, due to bias, not conclusive (Cuijpers, 
Reijnders, and Huibers 2019; Okumura and Ichikura 2014; Yang et al. 2017). Despite the 
criticism, it is also argued that CBT is based on rigorous empirical basis (David, Cristea, and 
Hofmann 2018) and is considered valid (Chand, Kuckel, and Huecker 2020; Lopez and Basco 
2014; Titov et al. 2018; Tay, Subramaniam, and Oei 2019). 
On the other hand, with CBT 55% of patients with social anxiety disorder responded, and 
15% achieved remission (Hunger et al. 2019). Upon that, the meta-analysis showed that 
response occurs in approximately 50% of all clients that are administered iCBT, whereas 
about a third reach remission, and a quarter fail to respond (Andersson, Carlbring, and 
Rozental 2019; Rozental, Andersson, and Carlbring 2019). When used as a second-line 
treatment, the success rate in the UK was found to be at 52% (Gyani et al. 2013). Finally, the 
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European Association of Psychotherapy references an average success rate of 65% to 72% 
(Carr 2012). Even though online therapy room approach has an odds ratio of only 1.1, the 
odds ratio for face-to-face intervention is between 2.5 and 3.0 (Carpenter et al. 2018; Ewbank 
et al. 2020; Santoft et al. 2019). Hence, the effectiveness should not be lower than that of 
pharmacological approach. To conclude, iCBT proved effective across 4 main disorders: 
major depression, generalized anxiety disorder, social anxiety disorder and panic disorder 
(Andrews et al. 2018).  
ALPHA-STIM® DEVICE FOR ANXIETY, INSOMNIA, DEPRESSION AND PAIN 
Alpha-Stim is a cranial electrotherapy stimulator (CES), produced by Electromedical 
Products International, Inc (EPI). The NHS is the most recent organism to recognize Alpha-
Stim, after a clinical effectiveness and economics study conducted by the National Institute 
for Health Research (NIHR), published in the Journal of Affective Disorders, provided 
favourable results (add reference). Subsequently, an innovation briefing was developed by 
The National Institute for Health and Care Excellence (NICE), specifying that the current care 
pathway would be changed to start providing the device through primary care and mental 
health services for patients to use at home (NICE 2019). The brief includes comments from 
specialists and patient organizations, noting the potential for Alpha Stim to be used by those 
who do not want to undergo pharmacological or psychological treatments, to reduce the need 
for psychological treatment and to reduce the cost of care. NICE MedTech guidance is 
currently under development and includes 42 registered stakeholders, from patient 
organizations to professional groups and the manufacturer.  
The U.S. Food and Drug Administration (FDA) reclassified Alpha Stim from the risk III class 
into a less risky II class just 6 months ago (Federal Register 2019). Based on a review of the 
scientific literature, the FDA concluded that there is reasonable assurance of safety and 
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effectiveness of CES devices. This decision was accompanied by 303 testimonials, mostly 
coming from board certified medical doctors, therapists and researchers, and can be accessed 
on the Federal Register’s webpage. In the US, the medical device is extensively used by the 
US Army, with every single deployed unit being equipped with one (Chicago Psychology 
Podcast 2020). A colonel and chief psychologist of the US Army Reserve testified to the 
FDA: “In my experience, without exception, there is no more powerful form of therapeutic 
intervention, either as an adjunct or a stand-alone treatment, than Alpha-Stim” (FDA 2012). 
While in the US the device is obtainable solely if prescribed, in Europe Alpha-Stim is IIa 
classified, which means that it can be sold freely in any store. It goes without saying that also 
in Europe, the Directive (93/42/EEC) and accompanying Guidelines demand sufficient 
clinical evidence to confirm compliance with safety and performance requirements. In 
Slovenia, Alpha-Stim has been used by individual psychiatrists since early 2018, and it has 
been distributed in selected European countries for even longer.  
Even though interactions between electrical and chemical synapses are likely to have 
important pathological implications, we are still far from understanding the full scope of their 
prevalence (Nagy, Pereda, and Rash 2018; Pereda 2014). Currently a registered PTSD trial is 
underway (ClinicalTrials.gov 2019). The results from a recent systematic review supported 
the notion that CES is safe, and provided suggestive evidence of a beneficial association in 
patients with anxiety disorders and major depression (Shekelle et al. 2018). Alpha-Stim safety 
and efficacy is supported by over 100 research studies, most done by independent researchers 
who have attained institutional review board (IRB) approval without funding by EPI 
(Marksberry 2018), of which NICE referenced 4. The NHS study was partially funded by the 
manufacturer, but any other role or conflict of interest were negated (Morriss et al. 2019).  
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Finally, it is important to differentiate between CES devices with different settings/treatment 
parameters and to note that Alpha-Stim has a patented waveform (Mischoulon et al. 2015) 
(Patent no.: US 8,612,008 B2).  
For anxiety and depression symptoms, the efficacy of Alpha-Stim ranged from 48% for NHS 
patients that had not reached remission with a therapist or full guided self-help to 82% in a 
randomized, 5-week double blind, placebo controlled study (Barclay and Barclay 2014; 
Morriss et al. 2019). The NHS study found that 63% of patients achieved reliable 
improvements at 12 weeks, with most of the effect experienced in the first 6 weeks. CES was 
found to be effective against anxiety and depression symptoms, with rates of remission being 
only 13% lower than that of iCBT but with a 42% lower cost (Morriss et al. 2019). 
Furthermore, a pending publication of a retrospective study by Morris & Price for subjects 
with generalized anxiety disorders and comorbid depression showed that on the Patient Health 
Questionnaire (PHQ-9) basis, 72% of depressed patients achieved remission by week 12 and 
80% by week 24. Finally, only 2.5% experienced side effects. The device’s user manual 
explains that no significant lasting side effects have been reported. An occasional headache, 
discomfort or skin irritation under the electrodes or light-headedness may occur (EPI 2020a).  
CURRENT STATE OF PSYCHIATRIC CARE IN SLOVENIA 
Epidemiological review 
Psychotherapeutic services are urgently needed by 5% of Slovenian adult population and less 
urgently by 20%. This means that 100,000 Slovenians are in urgent need of care. Since a 
psychotherapist can, on a conservative basis, see 15 to 30 patients per month, 5,000 
psychotherapists would be needed, although on the basis of the European Association for 
Psychotherapy’s more conservative estimate the number drops to “only” 2,000 (Možina 
2010). This estimation can only be a best-case scenario if no other treatments were utilized. 
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For comparison, Switzerland, being the European country with by far the most psychiatrists, 
has 51.72 per 100,000 inhabitants (Eurostat 2020). If Slovenia had the same, 1,076 would be 
providing psychotherapy.   
In the 2014 European Health Interview Survey (EHIS 2, second wave), 5.5% of Slovenian 
interviewees (15+ years) rated themselves as depressed. This low “prevalence” is probably 
due to self-reporting; it is inconsistent with the fact that Slovenia is consistently among the 3 
countries in the EU with the highest rates of death by intentional self-harm (Eurostat 2016). 
The prevalence of depression is estimated at 12%, and it is believed that only up to 50% of 
people are getting treated.  
In 2018, 83,158 new cases of mental and behavioural disorders were identified at the primary 
care level, corresponding to 4% of the population (NIJZ 2019d). At the secondary outpatient 
level, 61,355 first psychiatric visits were made and further visits amounted to 251,183. Thus, 
for each first visit there were additional 4.1 follow-up visits on average (NIJZ 2019e). This 
ratio is topped only by the outpatient oncology.  
In 2018, SSRIs were prescribed to 7% of Slovenians, with an average prescription duration of 
79 days. According to the Anatomical Therapeutic Chemical Classification System (ATC), 
586 thousand prescriptions were made (code N06A) or 283 per 100,000, which amounts to 
11.1 million € and an average prescription value of 18.9 € (NIJZ 2019a). Applying the cost of 
a defined daily dose (DDD) to a minimum treatment duration of 6 months, the cost of SSRIs 
amounts to a minimum of 43 € per one full treatment. Anxiolytics, of which most are BZDs, 
were prescribed to 6.9% of Slovenians - 409 thousand times (code N05B) or 198 times per 
100,000, which in total amounts to 2.8 million euros or an average prescription value of 6.7 € 
(NIJZ 2019a). The average prescription duration is 24 days, as BZDs can cause dependence 
after 3 to 4 weeks (Brett and Murnion 2015).  
11 
 
Long waiting times 
Waiting for treatment has become a defining characteristic of Slovenian health care. Based on 
the EHIS (wave 2), the prevalence rate of unmet health care needs that was due to long 
waiting lists was estimated at 19.6% of the population, being the highest of all causes (NIJZ 
2019f).  The maximum permissible waiting times are set at 14 days for “very quick,” at 3 
months for “quick” and at 6 months for “regular” referrals (Rules on the Referral of Patients, 
the Management of Waiting Lists and the Maximum Permissible Waiting Times 2018). These 
limitations are lifted for (routine) check-ups at later appointments, for which no data is 
provided. In psychiatric care, the queues have been unacceptably long over the years (Polanec 
Klemen 2019). The National Institute of Public Health (NIJZ) publishes queue reports 
monthly, and the last available is of March. The average waiting times for the first psychiatric 
appointment were as follows: 92.5 days with “regular,” 57.6 days with “quick” and 36.6 days 
with “very quick” referral, with the total number of patients on the waiting list amounting to 
2,131. In addition, 264 patients (12.39%) had been waiting above the permissible limits.  
In the first section of article 2.2 of the Resolution on the National Mental Health Program 
2018-2028 (RNMHP), it is written: “The waiting times, especially for psychotherapy, are 
long. The field of psychotherapy is not regulated in Slovenia; the Health Insurance Institute of 
Slovenia (ZZZS) recognizes the cost of this service only to clinical psychologists and 
psychiatrists. There are too few clinical psychologists, as only one in three psychologists is a 
specialist in clinical psychology. The specialization of clinical psychology depends on the 
interest of practitioners and does not rest on the actual needs of the population.” Patients can 
wait on recurring examinations and therapies for up to a year, and considering the current 
outlook, psychotherapy is by all means reserved only for those able to afford it (24UR 2017). 
Based on the European Quality of Life Survey (EQLS 2016) responses about the difficulty in 
affording psychological or psychiatric services, the only 2 countries that ranked worse than 
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Slovenia on EU-28 level were Greece and Cyprus (Ludwinek, Sandor, and Clevers 2019). 
The report mentions that due to this reason, the young people (18-24 years) in these countries 
would not even consider turning to support services for mental health issues. This is very 
alarming, as almost 40% experience their first episode of depression before the age of 20 
(Malhi and Mann 2018). This means that besides pharmacotherapy, patients are presented 
with 2 choices: to suffer in long waiting lines in the public sector or to pay out of their pocket 
and seek treatment from private providers, some of dubious professional backgrounds, using 
pseudoscientific methods, causing even more psychological pain (Polanec Klemen 2019).  
Severe shortage of staff 
The number of patients is increasing and there are too few psychiatrists, about 50% of the 
European average (ZZZS 2019), which implies that 315 more are needed. If instead of the EU 
average, Swiss level would be targeted, 760 would be needed. While in 2017 Switzerland had 
52 psychiatrists per 100,000 inhabitants and Germany 27, Slovenia had only 14 (Eurostat 
2020). Note that this number includes all training statuses and all industries. When counting 
only fully certified adult specialists, Slovenia is left with only 207 out of the 277 professionals 
(NIJZ 2019b). As shown in Tables 6 - 8, the number of professionals has been increasing but 
way too slowly to have any noticeable impact. Counting all the psychiatrists, to achieve the 
German level Slovenia would need an additional 254 psychiatrists. In addition to the staff 
shortage, burnout is an issue, as working conditions are getting unbearable. As new specialists 
appear nowhere to be found, the psychiatric hospital Vojnik is conducting interviews with 
specialists from abroad. Future outlooks are unfavourable and the announced vacancies for 
specialists in training are not going to meet the increasing needs (RTV Slovenija 2019).  
As already mentioned, ZZZS recognizes psychotherapy services only to psychiatrists and 
clinical psychologists and not to unspecialized psychologists, who are not allowed to 
diagnose. In general, they (only) provide psychological evaluations in terms of occupational 
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medicine. Psychologists with or without clinical specialization are not allowed to prescribe 
medications. Because clinical psychologists are not recognized as medical doctors, the 
government does not provide funding for their specialization and institutions must finance it 
themselves, which costs around of 150,000 € (Vignjevič Pupovac 2019). Based on the 2018 
report on resources, Slovenia had 4.7 clinical psychologists per 100,000 inhabitants, 97 in 
total. When counting only fully certified adult specialists employed in the health service, 73 
are left (NIJZ 2019b). To put things in perspective; the UK has 17, while Norway has 62 
clinical psychologists per 100,000 inhabitants (Polanec Klemen 2019). Slovenia is thus at the 
European bottom (Čoderl Dobnik 2020). Finally, the number of forensic psychologists (expert 
witnesses) is so low that the Human Rights Ombudsman of the Republic of Slovenia is 
warning about a possible human rights violation (STA 2019c). 
Substantial regional differences in service accessibility 
Regional differences in service accessibility are quite high in Slovenia; they are shown in 
Tables 4 - 5 and Figures 3 - 4. Regions with higher risk tend to have smaller numbers of 
psychiatry specialists, generally above-average disease identification at the primary care level 
and below-average identification at the secondary care level. Regional variations (measured 
by the percentage point difference between the best and the worst regions) are the lowest in 
outpatient antidepressant prescription, followed by anxiolytics prescription, because these 
prescriptions can also be made by general practitioners. On the contrary, the variations are the 
highest in the numbers of clinical psychologists. One may conclude that while accessibility to 
pharmacological treatment is relatively equal across regions, the opposite is true for 
professional psychological or psychotherapeutic care. This could lead to tremendous 




Absenteeism, sick leave and statutory social security 
For full-time employees in Slovenia, mental and behavioural disorders accounted for 995,596 
lost workdays in 2018. Mental and behavioural disorders are the 3rd biggest cause of sick 
leave and represent the 4th longest sick leave duration, on average 46.3 days. This compares to 
average duration of leave in case of pregnancy and delivery of 54 days, whereas a general 
average is of 16.4 days (NIJZ 2019c).  
When it comes to hospitals beds, psychiatric care comes 3rd (NIJZ 2019b). Furthermore, 
psychiatric illnesses are the second cause of all permanent disability cases (ZPIZ 2020). 
The Resolution on the National Mental Health Program (RNMHP 2018-28) and outlook 
The Resolution on the National Mental Health Program (2018-28) should enable equal 
accessibility to mental health facilities for all residents and address the increasing number of 
patients, stigma, lack of experts, long-term hospitalizations and absenteeism from work, 
numerous institutionalizations and the low number of persons with mental disorders included 
in the labour market (K. Juričič et al. 2018). This would be mainly achieved by financing 
teams for 50 new regional mental health centres (RMHCs), 7 subspecialist outpatient teams 
complementing 22 already existing interdisciplinary teams, amounting to a yearly cost of 97.8 
million € at the end of RNMHP (18-28). In 2018, ZZZS spent 63.06 million € on mental 
health, corresponding to 2.25% of total healthcare budget or 3.03 € per capita (Zupanič 
Milena 2018). The comparison between the proposed and the accepted budget is given in 
Table 10. In Europe, the average spending on mental health amounts only to 1% of total 
health spending by governments, with 69% of it going to psychiatric hospitals (WHO 2019).  
In spite of a what should end the “considerable chaos” (Janičijević 2018) and start the 
“revolution in Slovenian mental health care” (Zajec 2018), the realization of the clinical 
psychology program was, according to the ZZZS, low (91.48%). In its yearly business report 
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for 2019, published in March 2020, ZZZS also remarks that: “In practice, it turned out that on 
the labour market, the RMHCs were not able to acquire the majority of the projected labour 
force needs, so the funding was reduced for the missing staff. This brings us to the question if 
in the light of the human resources shortage, it is realistic to expect that the centres’ teams 
will be successfully assembled and if the currently agreed arrangement of this field is even 
appropriate” (fifth section of Article 1.4.1.1). Thus, the RMHCs have been opening in a 
reduced structure, and psychologists without the specialization will, under the supervision of a 
mentor, substitute clinical psychologists, which happened without the consent of the 
professional community, because psychologists are required to perform work for which they 
are not qualified (Polanec Klemen 2019; Vignjevič Pupovac 2019). Thus, the Chamber of 
Clinical Psychologists believes that the NHMBR will not deliver what it promised, and The 
National Youth Council of Slovenia states that although highly needed, the mental health 
remains at the bottom of  the government’s priorities (NYCS 2019; Polanec Klemen 2019).  
COST QUANTIFICATION OF ALPHA-STIM IMPLEMENTATION 
In Europe, the total cost of mental health problems was estimated at more than 4% GDP, of 
which 32% represent direct healthcare costs, 19% direct costs to social security and 49% 
indirect labour market costs — i.e. sick days and disability, early retirement, undetected 
decreases in productivity (OECD/EU 2018). Thus, effective treatment may have substantial 
consequences outside immediate treatment settings (Knapp and Wong 2020; Sobocki et al. 
2006; Wittchen et al. 2011a). From the employers perspective, 2 separate large-scale 
randomized workplace depression treatment trials found positive returns-on-investment 
(Kessler 2012). As for  the treatments, iCBT has been found to be the most cost-effective 
intervention even without considering the side-effects of drugs (Heuzenroeder et al. 2004; 
Mavranezouli et al. 2015; Yan et al. 2019), and an Alpha-Stim intervention in the NHS setting 
was found to be even more cost-effective (Morriss et al. 2019).  
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Psychotropic non-adherence is a widely known phenomenon, with 50% of patients not taking 
antidepressants as prescribed (Sansone and Sansone 2012; Semahegn et al. 2020). In the US, 
non-optimized medication therapy was estimated to represent an annual cost of 528.4 billion 
$, equivalent to 16% of total 2016 US health care expenditures (Watanabe, McInnis, and 
Hirsch 2018). Thus, non-adherence is a significant challenge for patients with psychiatric 
disorders, physicians and healthcare systems and places a large resource burden on healthcare 
systems (Chapman and Horne 2013; Lloyd et al. 2019). Alpha-Stim has a non-resettable 
cumulative timer, allowing for usage control and better adherence. 
Methodology 
To determine the cost impact of introducing CES into the care pathway for mental disorders 
in Slovenia, as a second-line treatment instead of or prior to a second-line iCBT, a cost 
minimization analysis was undertaken using a health economics model decision tree (Fig. 1). 
The second-line comparison is made because it is the most realistic nationwide 
implementation option at the time, and because it allows for a results comparison between the 
UK and the former Yugoslavian country, with much lower wages and thus lower iCBT costs. 
For iCBT, a remission rate of 54.2% was used, which is the average remission rate between 
guided and full self-help groups in the study by Gyani et al. 2013. For the second-line use of 
Alpha-Stim, the response rate ranged from 47.2% for depression to 63.4% for anxiety but the 
former was utilized (the conservative approach and similarly to Morriss et al. 2019).  
To estimate the cost of iCBT, actual patient data was obtained from moj.zzzs.si portal 
(“my.zzzs.si”), a user accessible portal of the National Health Insurance Institute providing 
patients with transparent and accurate insights into costs of their service utilization. For each 
1-hour session, 3 distinctive service codes are used (96190, 11305 and 02003/05), which 
checked against the latest ZZZS’s code register (ZZZS 2020b), and the official 2020 price list 
(ZD Koper 2019) results in a total cost of 48.68 €. For the medical device, the total cost was 
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set at 70 € ex./VAT per a 12-week treatment, including the supplier’s reimbursement, 
consumables, postage and 13.7 € worth of additional specialist time, valued through service 
codes (11305 for treatment continuation, 02003/05 for examination and 91100 for making a 
prescription). For non-responders to second-line iCBT, a further course of the same number 
of iCBT sessions would follow (8 and 10 sessions were compared), with the same/constant 
remission probability. For non-responders to second-line CES, up to two further courses of 
iCBT were included in the decision tree. Nevertheless, results are provided also for the case if 
only 1 or none further iCBT courses followed. 
Next, to estimate staff and Alpha-Stim needs at the national level, a top-down approach was 
utilized1. Hence, the number of missing psychiatrists was estimated on the basis of the EU 
average (315) (ZZZS 2019), the German level (250) and a basic arbitrarily set need (150). The 
estimate of how many patients one psychiatrist could treat in a year is based on the normative 
duration of 1 session being 1 hour (Psychiatric Association of Slovenia 2017), 224 workdays, 
7 hours of daily productive time and provided for 2 treatment duration scenarios: 8-session 
(Option A) and 10-session iCBT (Option B). Based on these assumptions, 1 specialist could 
provide iCBT treatment for 157-196 patients per year. Because the device was found to be 
13% less effective on the secondary level than iCBT, effectiveness was adjusted so that the 
original number of devices needed was increased accordingly. Since 1 Alpha-Stim can 
provide four 12-week treatments in a year, the need is estimated with a scenario analysis 
provided for all previously mentioned options. Finally, since effective treatment has even 
greater effects on employment-related costs than the direct healthcare cost, a basic budget 
impact analysis was done (Woo et al. 2011). Note that in Slovenia, the employer must cover 
the first 30 days of sick leave, and ZZZS pays only for the subsequent days. ZZZS is also the 
institution that would cover the costs of the Alpha-Stim implementation.  
1A bottom-up approach was hampered by lack of data (e.g. how many patients receive iCBT).  
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It was estimated that the implementation of RNMHP 11-16 would decrease the number of 
hospitalizations by 10%, decrease their duration by 3% and reduce the number of sick days by 
10%. In our case, only the decrease in sickness absence was quantified and is provided as a 
scenario analysis in Table 2. Pay-outs are based on the average gross salary of 1,799.66 € and 
the official 90% gross salary compensation (SURS 2020; ZZZS 2020a). Furthermore, an 
opportunity cost reduction was quantified through a trickle-down effect from an incremental 
increase in net added value per worker for the reduced absence duration, via corporate tax of 
19%, to the ZZZS through its governmental budget participation of 7.7% (AJPES 2019; 
EUGO 2020; Ministry of Finance 2020).  
Results 
When Alpha-Stim is compared to 8-session iCBT solely on the first round’s head-to-head 
basis, 1,000 patients could be treated without therapists for 319,400 € less, at an incremental 
loss of 70 patients that do not respond to treatment (Fig. 1). Next, if Alpha-Stim is introduced 
as a second-line intervention prior to a double round second-line iCBT, a cost reduction of 
198 € per patient is observed. With 1,000 patients, a cost saving of 198,000 € is achieved, 
with 99 more patients responding. The threshold price is 268 €. Finally, if Alpha-Stim is used 
instead of just the 1st-legged iCBT, an additional incremental saving of 94.000 € is observed 
but at an incremental cost of 131 not responding. The threshold price is at 362 €.  
When Alpha-Stim is compared to a 10-session iCBT solely on the first round’s head-to-head 
basis, 1.000 patients could be treated without therapists for 416.800 € less, at an incremental 
loss of 70 patients (Fig. 2). Next, if Alpha-Stim is introduced as a second-line intervention 
prior to a double round second-line iCBT, a cost reduction of 198 € per patient is observed. In 
a pool of 1.000 patients, a cost saving of 198 thousand € is achieved, with 99 more patients 
responding. The threshold price is for this case 268 €.  
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Finally, if Alpha-Stim is used instead of just the 1st-legged iCBT, an additional incremental 
saving of 94 thousand € is observed but at an incremental cost of 131 patients not responding. 
The threshold price is for this case at 362 € per treatment.  
Regarding the results for overall care needs at the national level, the number of yearly 
treatments needed was estimated between 79,966 and 27,034, the number of devices needed 
between 17,741 and 6,759 and the direct Alpha-Stim costs between 1.89 million and 4.97 
million €, depending on treatment duration (Option A or Option B). The intermediate values 
of these intervals were used for the analysis: 49,000 for treatments needed, 12,250 for devices 
needed, and 3.43 million € for the direct Alpha-Stim costs.  
To provide a regional perspective, the number of circulating devices was broken down to the 
municipal level for 2 Slovenian statistical regions and epidemiologically compared (Table 1).  
Lastly, the budget impact analysis is presented in Table 2. Based on the results, the direct 
social security cost savings were estimated at 10.14 million € for a 15% reduction in the 
average duration of sick leave, while the indirect opportunity benefits were estimated at 339 
thousand, together amounting to a 10,5 million € net monetary benefit to the ZZZS’ budget.  
Thus, the direct yearly average Alpha-Stim cost of 3.43 million € derived from the health 
economics decision tree for 2-round 8-session iCBT is more than 3 times offset solely by the 
social security budget impact. Factoring in the average number of additional yearly treatments 
needed (49.000), multiplied by an individual net cost benefit of 198 €, gives “direct” cost 
savings of 9.70 million € that could be obtained. Since this effect would be accompanied by 
the mentioned indirect impact on the social security budget of another 7.30 million to 10.48 
million € (for a 10% or a 15% reduction in sick-leave duration), the final yearly net cost effect 

























 Table 3: Direct costs impact as average of 
scenario analysis.  
 
Inhabitants National weight
EU level scenario: MAX number 
of AS devices in circulation
Basic level scenario: MIN number 
of AS devices in circulation
Average number of AS
devices in circulation
Average number of people with 
at least 1 prescription of SSRI
Average number of people with at 
least 1 prescription of anxiolytic
Average number of 
monthly AS treatments
Average monthly cost 
of AS treatment in EUR
Region: Obalno-kraška 114.085 5,48% 973 371 672 7.986 7.872 448 31.355
Ankaran 3.216 0,15% 27 10 19 225 222 13 884
Divača 4.093 0,20% 35 13 24 287 282 16 1.125
Hrpelje - Kozina 4.426 0,21% 38 14 26 310 305 17 1.216
Izola 16.099 0,77% 137 52 95 1.127 1.111 63 4.425
Komen 3.523 0,17% 30 11 21 247 243 14 968
Koper 51.828 2,49% 442 168 305 3.628 3.576 203 14.244
Piran 17.613 0,85% 150 57 104 1.233 1.215 69 4.841
Sežana 13.287 0,64% 113 43 78 930 917 52 3.652








Ajdovščina 19.154 0,92% 163 62 113 1.341 1.322 75 5.264
Bovec 3.052 0,15% 26 10 18 214 211 12 839
Brda 5.613 0,27% 48 18 33 393 387 22 1.543
Cerkno 4.584 0,22% 39 15 27 321 316 18 1.260
Idrija 11.730 0,56% 100 38 69 821 809 46 3.224
Kanal 5.300 0,25% 45 17 31 371 366 21 1.457
Kobarid 4.097 0,20% 35 13 24 287 283 16 1.126
Miren - Kostanjevica 4.885 0,23% 42 16 29 342 337 19 1.343
Nova Gorica 31.691 1,52% 270 103 187 2.218 2.187 124 8.710
Renče - Vogrsko 4.345 0,21% 37 14 26 304 300 17 1.194
Šempeter - Vrtojba 6.201 0,30% 53 20 37 434 428 24 1.704
Tolmin 11.108 0,53% 95 36 65 778 766 44 3.053








Average sick days duration 46.34
Average duration that falls on ZZZS 16.34
Workdays in a month 20.75
Number of cases 21,484
Gross salary (EUR) 1,799.66
Compensation 90.0%
Corporate tax 19.0%
ZZZS budget participation 7.7%
Average yearly net added value per worker 44,415.00










ZZZS total net 
benefit
Current 27,401,988 €  -  €                -  €                  -  €               -  €                 -  €                    
With a 5% duration reduction 23,701,434 €  3,700,554 €    8,456,335 €       1,606,704 €    123,716 €         3,824,270 €        
With a 10% duration reduction 20,337,294 €  7,064,694 €    16,143,913 €     3,067,343 €    236,185 €         7,300,880 €        
With a 15% duration reduction 17,265,688 €  10,136,300 €  23,163,006 €     4,400,971 €    338,875 €         10,475,175 €      
With a 20% duration reduction 14,450,049 €  12,951,939 €  29,597,174 €     5,623,463 €    433,007 €         13,384,946 €      
Assumptions
Average between MAX of OPTION A and MIN of OPTION B - national level
Average number of psychiatrist missing
233
Average yearly number of treatments (also patients)
49,000
Average number of devices needed
12,250
Average monthly number of treatments
4,083
Average monthly point in time prevalence of AS treatment
0.39%
Average yearly direct cost of implementation
3.43 million €




Of course, multiple other opportunity costs could be accounted for, which is the main 
limitation of this analysis. As already mentioned, clinical specialization costs an institution 
150.000 €. Distributed across a 35-year career, ZZZS would, on a yearly basis, need to spend 
4,286 € per doctor, which was not accounted for in the decision tree.  
Since Alpha-Stim reduces the number of specialists needed by 50%, this could result, 
roughly, in yearly savings of 0.5 million €. Of course, if Slovenia were to channel all its 
medical students to psychiatry to fill the shortage as soon as possible, other great opportunity 
costs would occur in the form of staff shortages for treating other important conditions.  
Next, according to the NIJZ’s representative, every euro invested in the preventive social 
programs used in the RNMHP (18-28) has 33 to 80-fold return (Zajec 2018). This means that 
if a net monetary benefit of at least 17.5 million € is invested in these programs, a final net 
impact of at least 577 million € could be assumed in the long run. Therefore, Alpha-Stim 
implementation could provide an even more substantial value proposition from multiple 
additional viewpoints in addition to potentially solving the current stalemate state of 
Slovenian psychiatry in a cost-effective manner.  
Next, if Alpha-Stim were implemented to completely replace iCBT, according to the first-
round head-to-head comparison coupled with a 5% duration reduction, 24.2 million € would 
be the minimum final net yearly benefit; 38% higher than in the previously mentioned option 
of using Alpha-Stim prior to a 2-round iCBT but at the expense of 47% less patients 
responding (472 vs. 890 in a pool of 1.000 patients).  
Finally, the pathway could be optimized by dynamically allocating patients based on their 
individual preferences and characteristics, thus improving the likelihood of successful 
response for both options simultaneously. For example, if one prefers human interaction or is 




The demand for psychiatric services in Slovenia is increasing, the waiting lines are 
exceedingly long, and the shortage of specialists is severe and unequal across regions. It 
seems that Slovenia has reached a stalemate position, where creating a large pool of 
specialists in psychiatry would result in high opportunity costs at the expense of other 
specializations that are also critically understaffed (STA 2019a; 2019b).   
Considering everything, it is hard to believe that Slovenia is prepared for the after-effects of 
what seems to be the largest pandemic of our time. Hence, professional warnings about the 
aftermath of Covid-19 should be taken even more seriously. One of the warnings was 
published last month in Lancet Psychiatry, stating that the epidemic has caused a parallel 
epidemic of fear, anxiety and depression (Yao, Chen, and Xu 2020). Another similar warning 
comes from the editor-in-chief of the American Journal of Current Psychiatry. Even the 
Chinese, Singaporean and Australian governments have voiced concerns that the long-term 
psychological side effects of Covid-19 and isolation could cause more harm in the community 
than the virus (Zhou et al. 2020). A list of other academically published warnings about the 
parallel epidemic is provided in the Appendix. In Slovenia, even though free psychological 
support helplines are being offered, the majority of consultations have been suspended and the 
new regional mental health centres were no exception. The NIJZ’s update on monthly waiting 
times is running late. 
Given the burden of poor mental health, the economic case for preventing mental illnesses 
and promoting better mental health may be very strong, but too often it attracts little attention 
and few resources (Chisholm et al. 2016; McDaid, Park, and Wahlbeck 2019). Hence, there is 
still a substantial unmet need, especially among treatment-resistant depression patients in 
Europe (Jaffe, Rive, and Denee 2019). Alpha-Stim is a cost-effective, transportable, pocket-
sized, readily available and clinically tested treatment intervention that can also help improve 
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regional discrepancies in service accessibility as well as provide a new treatment option 
which may be more appropriate to some patients.  
To put the estimated direct yearly costs of nationwide Alpha-Stim implementation into 
perspective, it represents less than a quarter of Slovenian yearly spending on antidepressants 
and anxiolytics, less than 10% of what would need to be spent just on specializations, less 
than 4% of total costs planned at the end of the RNMHP (18-28) and less than 2% of what 
was spent on personal protective equipment during the Covid-19 pandemic. The RNMHP 
planned for ZZZS to gradually increase investment in mental health from 63.1 to 97.8 million 
€, which due to staff shortages turned out to be unfeasible. Hence, 3.5 million € is a minor 
direct cost for an estimated net benefit of at least 18 million €, offsetting no less than 50% of 
the RNMHP’s planned cost increase. While NICE guidance is being prepared by a mix of 
more than 40 organizational stakeholders, in Slovenia the decision on Alpha-Stim 
implementation will be left in the hands of 5 psychiatrists constituting the Ministry of 
Health’s General Advisory Board for Psychiatry and a ZZZS’ committee. Furthermore, at the 
beginning of 2020, EPI’s application for a Healthcare Common Procedure Coding System 
(HCPCS) with the Centres for Medicare and Medicaid Services in the US was approved, and 
an insurance billing code for CES devices was issued (EPI 2020b). Private insurance 
companies are soon to follow (Chicago Psychology Podcast 2020). 
Researchers must work extra hard to find alternative methods for psychiatric treatment and 
both the NHS and the US Army have embraced the potential of Alpha-Stim medical 
technology (P. Nuse 2017). Since we are already stimulating our muscles to a speedy 
recovery after various injuries, doing the same to an organ that can generate enough electricity 
to power a low-wattage bulb (Hofman 2014) may be associated with less stigma than the 
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least 1 prescription 
of antidepressant




psychologists  per 
100,000 inhabitants
Number of clinical 
psychologists  per 
100,000 inhabitants
Number of child and 
adolescent psychiatrists  
per 100,000 inhabitants
Pomurska 12 4.8 3.4 8.5 7.4 4.4 9.6 4.4 0.0
Zasavska 11 4.9 1.5 6.9 8.1 3.5 5.3 0.0 1.8
Posavska 10 3.0 1.5 7.6 6.6 6.6 13.3 2.7 0.0
Primorsko-notranjska 9 4.6 0.9 7.7 7.1 3.8 3.8 0.0 0.0
Podravska 8 4.1 4.0 8.4 7.3 11.5 12.7 3.7 1.2
Savinjska 7 3.5 1.9 7.5 7.2 6.3 11.3 2.3 0.0
Koroška 6 4.6 0.3 7.9 7.7 5.7 8.5 2.8 1.4
Jugovzhodna Slovenija 5 4.2 2.0 7.4 6.9 3.5 7.0 1.4 0.0
Obalno-kraška 4 3.8 2.6 6.5 6.9 8.8 8.8 0.0 0.9
Gorenjska 3 4.6 3.0 5.1 6.7 10.8 8.4 6.4 0.5
Goriška 2 4.0 3.0 7.1 7.9 17.9 14.5 3.4 0.0
Osrednjeslovenska 1 3.7 4.6 5.7 6.5 14.3 23.3 6.6 1.3
Average 6.5 4.2 2.4 7.2 7.2 8.1 10.5 2.8 0.6
Data source: *A (2011) *B (2018) *C (2018) *D (2018) *D (2018) *E (2018) *E (2018) *E (2018) *E (2018)
Risk degree of 
developing 
mental disorder
% of people with identified 
mental or behavioral disorder at 
primary level (ICD-10 chapter V) 
% of people with identified mental 
or behavioral disorder at 
secondary level (ICD-10 chapter V) 
% of people with at 
least 1 prescription 
of anxiolytic
% of people with at 
least 1 prescription 
of antidepressant




psychologists  per 
100,000 inhabitants
Number of clinical 
psychologists  per 
100,000 inhabitants
Number of child and 
adolescent psychiatrists  
per 100,000 inhabitants
Pomurska 84.6% 15.2% 42.6% 18.2% 2.9% -46.1% -8.9% 55.2% -100.0%
Zasavska 69.2% 19.1% -39.4% -4.1% 12.6% -56.6% -50.1% -100.0% 197.7%
Posavska 53.8% -27.8% -38.5% 5.7% -8.2% -18.0% 25.8% -5.6% -100.0%
Primorsko-notranjska 38.5% 11.2% -62.4% 7.1% -1.3% -52.7% -63.7% -100.0% -100.0%
Podravska 23.1% -0.9% 68.1% 16.8% 1.5% 42.1% 20.9% 32.6% 111.0%
Savinjska 7.7% -15.5% -21.4% 4.3% 0.1% -22.6% 7.6% -16.5% -100.0%
Koroška -7.7% 9.8% -85.8% 9.8% 7.1% -29.9% -19.3% 0.8% 140.5%
Jugovzhodna Slovenija -23.1% 0.4% -16.8% 2.9% -4.1% -56.9% -33.8% -50.4% -100.0%
Obalno-kraška -38.5% -7.9% 9.1% -9.6% -4.1% 8.4% -16.8% -100.0% 48.9%
Gorenjska -53.8% 10.6% 26.3% -29.1% -6.8% 33.7% -20.7% 127.2% -16.6%
Goriška -69.2% -4.2% 27.1% -1.3% 9.8% 121.3% 37.5% 21.3% -100.0%
Osrednjeslovenska -84.6% -9.7% 91.1% -20.7% -9.6% 77.3% 121.6% 135.5% 118.5%
Average 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Max difference (p.p.) / 46.9 176.9 47.3 22.2 178.2 185.3 235.5 /
Diff. 4 high/low (p.p.) / 29.3 113.7 28.9 15.3 121.7 93.5 175.2 /
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Figure 3: Percentage points differences of maximum regional relative deviations from the 











Interpretation: Perc. point difference is for number of psychiatrists per 100.000 inhabitants 
highest between Goriška (+121,3%) and Jugovzhodna Slovenija region (-56,9%) and is 178,2.  
Source: Own calculations based on Table 4 and 5.  
 
Figure 4: Percentage points differences of relative deviations from the average access to 










Interpretation: 121,7 is the perc. points difference for number of psychiatrists per 100.000 
inhabitants between the average values of 4 highest (68,6%) and 4 lowest regions (-53,1%). 
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Dark blue = relates to secondary level
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Table 6: Total number of adult psychiatrists in Slovenia, by the training status. 
 
Source: NIJZ Data portal https://podatki.nijz.si/pxweb/sl/) and Statistical Office of the 
Republic of Slovenia (https://pxweb.stat.si/). 
Note: While Table 1 and 2 only include specialists with finished training, that were working 
in healthcare related institutions in 2018 (207), this table includes them all no matter the 
training or industry  status, i.e. also governing bodies and ministries, educational institutions, 
the pharmaceutical industry, and other non-medical organizations (277). 
 
 
Table 7: Total number of child and adolescent psychiatrists in Slovenia, by training status. 
 
Source: NIJZ Data portal https://podatki.nijz.si/pxweb/sl/) and Statistical Office of the 
Republic of Slovenia (https://pxweb.stat.si/). 
Note: While Table 1 and 2 only include specialists with finished training, that were working 
in healthcare related institutions in 2018 (15), this table includes them all no matter the 
training or industry  status, i.e. also governing bodies and ministries, educational institutions, 
the pharmaceutical industry, and other non-medical organizations (39). 
 
 
Year Specialists Specialist registrar (in training) Total adult psychiatry specialists Adult psychiatrists per 100,000 inhabitants
2005 179 31 210 10.4
2006 175 28 203 10.0
2007 172 21 193 9.5
2008 179 22 201 9.9
2009 186 25 211 10.3
2010 184 25 209 10.2
2011 187 32 219 10.7
2012 181 43 224 10.9
2013 195 43 238 11.5
2014 194 42 236 11.4
2015 196 47 243 11.8
2016 205 47 252 12.2
2017 206 50 256 12.4
2018 210 67 277 13.3
Year Specialists Specialist registrar (in training) Total child and adol. psychiatry specialists Child and adol. psychiatrists per 100,000 inhabitants
2005 0 3 3 0.1
2006 0 3 3 0.1
2007 0 4 4 0.2
2008 0 3 3 0.1
2009 1 3 4 0.2
2010 3 4 7 0.3
2011 3 4 7 0.3
2012 3 7 10 0.5
2013 5 9 14 0.7
2014 5 12 17 0.8
2015 7 17 24 1.2
2016 7 20 27 1.3
2017 10 19 29 1.4
2018 15 24 39 1.9
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Table 8: Total number of clinical psychologists in Slovenia, by training status. 
 
Source: NIJZ Data portal https://podatki.nijz.si/pxweb/sl/) and Statistical Office of the 
Republic of Slovenia (https://pxweb.stat.si/). 
Note: While Table 1 and 2 only include specialists with finished training, that were working 
in healthcare related institutions in 2018 (73), this table includes them all no matter the 
training or industry  status, i.e. also governing bodies and ministries, educational institutions, 
the pharmaceutical industry, and other non-medical organizations (97). 
 
 
Table 9: Total number of psychologists in Slovenia. 
 
Source: NIJZ Data portal https://podatki.nijz.si/pxweb/sl/) and Statistical Office of the 
Republic of Slovenia (https://pxweb.stat.si/). 
Note: While Table 1 and 2 only include psychologists that were working in healthcare related 
institutions in 2018 (266), this table includes them all no matter the industry  status, i.e. also 
governing bodies and ministries, educational institutions, the pharmaceutical industry, and 
other non-medical organizations (365). 
 
Year Specialists Specialist registrar (in training) Total clinical psychology specialists Clinical psychologists per 100,000 inhabitants
2005 86 6 92 4.5
2006 82 6 88 4.3
2007 82 4 86 4.2
2008 81 5 86 4.2
2009 84 4 88 4.3
2010 83 6 89 4.3
2011 81 5 86 4.2
2012 76 6 82 4.0
2013 75 6 81 3.9
2014 78 6 84 4.1
2015 81 8 89 4.3
2016 87 10 97 4.7
2017 81 10 91 4.4
2018 86 11 97 4.7

















Table 10: RNMHP (18-28) total costs comparison between suggested and accepted plan. 
 
Source: Official Gazzete and Ministry of Health of the Republic of Slovenia. 
 
Table 11: Yearly patient intake estimation if only 8 or 10-session iCBT would be performed.  
 
 
Table 12: Yearly number of treatments comparison.  
 
 





Year 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Marginal incrase 0 0 3.01 3.01 5.72 5.72 5.415 5.415 4.545 4.545 3.14 3.14
Yearly spending 63.06 63.06 66.07 69.08 74.8 80.52 85.935 91.35 95.895 100.44 103.58 106.72
ACCEPTED
Year 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Marginal incrase 0.00 0.00 4.75 4.21 3.87 3.54 3.55 3.68 3.51 3.87 2.41 1.32
Yearly spending 63.06 63.06 67.81 72.03 75.90 79.44 82.99 86.66 90.17 94.05 96.46 97.78
The Health Insurance Institute of Slovenia -The Resolution on the National Mental Health Programme 2018-2028 - total cost in million €
Workdays in a year 249 Frequency Monthly patient intake Yearly cycle repetition factor Yearly patient intake Average monthly intake
Question: How much patients can a specialist doing solely iCBT treat in a year?
Estimating monthly and yearly patient intake if only 8 or 10-session 60min iCBT therapy would be provided 
Assumptions Number of iCBT sessions needed: 8 --> OPTION A
Vacation days in a year 25 iCBT done daily 16.3 12,0x 196
Net yearly workdays 224 iCBT done weekly 32.7 6,0x 196
Working hours per day 8 iCBT done monthly 130.7 1,5x 196
Lunch time loss per day 0.5
Administrative time loss per day 0.5 Frequency Monthly patient intake Yearly cycle repetition factor Yearly patient intake Average monthly intake
Net productive hours 7 iCBT done daily 13.1 12,0x 156.8
Net workdays in a month 18.66666667 iCBT done weekly 32.7 4,8x 156.8
Net monthly productive hours 130.7 iCBT done monthly 130.7 1,2x 156.8




Number of patients treated if OPTION A
61,740 (MAX)
Question: How much specialists does Slovenia lack and how many patients could they treat?
Estimating yearly number of patients that would be treated, if a specific number of psychiatrists would be added into the healthcare system
Number of missing psychiatrist when compared to
the claimed EU average the German level the basic solution of specialists shortage
49,000 29,400
Number of patients treated if OPTION B
49,392 39,200 23,520 (MIN)
14,193 11,264 6,759 MIN
Estimating number of Alpha-Stim medical devices needed to obtain the same result
Number of 3-month treatments one Alpha-Stim medical device can do in a year
4
Number of devices needed when adjusted for cca. 13% lower effectiveness than iCBT
Number of Alpha-Stim devices needed to obtain the same result as missing psychiatrists would, if OPTION B and same effectiveness assumed
Number of devices needed when adjusted for cca. 13% lower effectiveness than iCBT
17,741 (MAX) 14,080
15,435 12,250 7,350
Number of Alpha-Stim devices needed to obtain the same result as missing psychiatrists would, if OPTION A and same effectiveness assumed


























Question: What is the number of effectiveness-adjusted treatments need and how much would they cost in a year?
Estimating total direct yearly cost of Alpha-Stim treatments to ZZZS
Total yearly number of Alpha-Stim treatments needed with adjusted effectiveness, if OPTION A
70,966 56,322 29,400
Total yearly direct cost of Alpha-Stim treatments quoted above (1 treatment = 70,0€, includes also 13€ of additional specialist time) in million EUR
4.97 (MAX) 3.94 2.06
Total yearly number of Alpha-Stim treatments needed with adjusted effectiveness, IF OPTION B
56,772 45,057 27,034
Total yearly direct cost of Alpha-Stim treatments quoted above (1 treatment = 70,0€, includes also 13€ of additional specialist time) in million EUR
3.97 3.15 1.89 (MIN)
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List 1: Published warnings on Covid-19 psychological crisis and parallel pandemic. 
(As of 27. 3. 2020). 
 
1) Management of corona virus disease-19 (COVID-19): the Zhejiang experience. 
       Xu K., et al. PubMed, 21. 2. 2020. 
“Therefore, we established dynamic assessment and warning for psychological crisis.” 
 
2) The Role of Telehealth in Reducing the Mental Health Burden from COVID-19. 
      Zhou X, et al. Mary Ann Liebert, 23. 3. 2020. 
“The Chinese, Singaporean, and Australian governments have highlighted the psychological side 
effects of COVID-19, and have voiced concerns regarding the long-term impacts of isolation and 
that the fear and panic in the community could cause more harm than COVID-19.” 
 
3) Psychological interventions for people affected by the COVID-19 epidemic. 
     Li D., et al. 19. 2. 2020. 
“Studies have confirmed that individuals who have experienced public health emergencies still have 
varying degrees of stress disorders, even after the event is over, or they have been cured and 
discharged from hospital, indicating these individuals should not be ignored.“ 
“Finally, owing to a shortage of professionals, the establishment of psychological intervention 
teams in many areas is not feasible.” 
 
4) Prevalence and predictors of PTSS during COVID-19 Outbreak in China Hardest-hit   Areas: 
Gender differences matter.  
   Liu N., et al. ScienceDirect, 16. 3. 2020.  
“The prevalence of posttraumatic stress symptoms (PTSS) in China hardest-hit areas a month after 
the COVID-19 outbreak was 7%. “ 
 “Therefore, we have reason to believe that the prevalence of PTSS among the public of the hardest-
hit areas will be more severe than the results of this study.”  
 
5) Recommended psychological crisis intervention response to the 2019 novel coronavirus 
pneumonia outbreak in China: a model of West China Hospital. 
      Zhang J. et al. Oxford Academic, 18. 2. 2020. 
“The absence of mental health and psychosocial support systems and the lack of well-trained 
psychiatrists and/or psychologists in these regions increased the risks of psychological distress and 




6) Progression of Mental Health Services during the COVID-19 Outbreak in China. 
      Li W., et al. IVYSPRING, 23. 2. 2020. 
“The outbreak of the COVID-19 has caused tremendous psychological problems in different 
subpopulations.” 
“Fourth, based on experiences of SARS outbreak, some patients and health professionals would be 
traumatized by the COVID-2019 outbreak and still suffer from persistent psychiatric symptoms 
even after the outbreak.” 
 
7) Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. 
   Xiang Y., et al. The Lancet, 1. 3. 2020 
“Health workers in a Beijing hospital who were quarantined, worked in high-risk clinical settings 
such as SARS units, or had family or friends who were infected with SARS, had substantially more 
post-traumatic stress symptoms than those without these experiences.” 
“In any biological disaster, themes of fear, uncertainty, and stigmatisation are common and may act 
as barriers to appropriate medical and mental health interventions. Based on experience from past 
serious novel pneumonia outbreaks globally and the psychosocial impact of viral epidemics, the 
development and implementation of mental health assessment, support, treatment, and services are 
crucial and pressing goals for the health response to the 2019-nCoV outbreak.” 
 
8) The National Health Commission has issued guidelines for emergency psychological crisis 
intervention for people affected by COVID-19. 
      Li D., et al. The Lancet, 18. 2. 2020.  
“The National Health Commission has issued guidelines for emergency psychological crisis 
intervention for people affected by COVID-19.” 
“After the assessment of the mental health states of individuals affected by the epidemic, patients 
cannot be assigned according to the severity of their condition and difficulty of treatment to the 
appropriate department or professionals for timely and reasonable diagnosis and treatment.” 
 
9) Public Mental Health Crisis during COVID-19 Pandemic, China. 
     Dong L., et al. Centers for Disease Control and Prevention, 23. 3. 2020. 
“Third, unprecedented large-scale quarantine measures in all major cities, which essentially confine 
residents to their homes, are likely to have a negative psychosocial effect on residents.” 
 
10) A Novel Approach of Consultation on 2019 Novel Coronavirus (COVID-19)-Related 
Psychological and Mental Problems: Structured Letter Therapy.  
        Xiao C. Psychiatry Investigation, 25. 2. 2020. 
“The epidemic brought to people in China and the world not only the risk of death after virus 
infection, but also unbearable psychological pressure.” 
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11) Mental Health Strategies to Combat the Psychological Impact of COVID-19 Beyond 
Paranoia and Panic.  
        Ho C, et al. Annals Academy of Medicine Singapur, 16. 3. 2020. 
“It is pivotal, however, that we do not ignore the psychological impact that the outbreak has on 
individuals and the society, which is often the limiting factor for the nation to overcome the crisis. 
Psychological ramifications can be long-lasting even after the epidemic has ended.” 
 
12) Online mental health services in China during the COVID-19 outbreak. 
        Liu S., et al. The Lancet, 18. 2. 2002. 
“One such multicentre survey involving 1.563 medical staff, with our centre at Nanfang Hospital, 
Southern Medical University (Guangzhou, China) as one of the study sites, found the prevalence of 
depression to be 50,7%, of anxiety to be 44,7%, of insomnia to be 36,1%, and of stressrelated 
symptoms to be 73,4%.” 
 
13) Patient Management and Clinical Recommendations During The Coronavirus (COVID-19) 
Pandemic. 
   Azziz R., et al. American Society for Reproductive Medicine, 17. 3. 2020. 
“The COVID-19 pandemic presents an unprecedented threat of unimaginable proportions to the 
psychological and emotional wellbeing of patients and staff.” 
“Mental health professionals should be utilized to help support patients and staff at risk for serious 
psychological or emotional issues.” 
 
14) The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus 
epidemic in China.  
     Y. Yang, et al. ScienceDirect, 3. 3. 2020. 
“The costs of the epidemic are not limited to medical aspects, as the virus has led to significant 
sociological, psychological and economic effects globally.” 
“One must not forget the psychological impact of an infection such as this on people who are not 
even infected or who will never encounter an infected person.” 
 
15) The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in 
Psychiatric Hospitals.  
     Zhu Y., et al. Springer Link, 25. 2. 2020. 
“Panic is inevitable among patients and medical staff and timely mental health care for dealing 





16) Psychological crisis intervention during the outbreak period of new coronavirus pneumonia 
from experience in Shanghai.  
     Jiang X., et al. ScienceDirect, 28. 2. 2020. 
“If medical care is delayed, affected persons may suffer inestimable damage caused by the 
psychological crisis.” 
“During the outbreak period of NCP, psychological crisis intervention (PCI) is urgently need for 
all affected, including patients, medical staff, close contacts, people in affected areas, as well as the 
general public.” 
 
17) COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, 
China.  
     Wang H., et al. BMC (part of Springer Nature), 18. 3. 2020. 
“It is crucial to ensure the stable psychological state of the medical staffs. Therefore, early 
professional intervention is necessary.” 
 
18) The mental health of medical workers in Wuhan, China dealing with the 2019 novel 
coronavirus.  
      Kang L., et al. The Lancet, 5. 2. 2020. 
“In the fight against the 2019 novel coronavirus (2019-nCoV), medical workers in Wuhan have 
been facing enormous pressure, including a high risk of infection and inadequate protection from 
contamination, overwork, frustration, discrimination, isolation, patients with negative emotions, a 
lack of contact with their families, and exhaustion. The severe situation is causing mental health 
problems such as stress, anxiety, depressive symptoms, insomnia, denial, anger, and fear. These 
mental health problems not only affect the medical workers' attention, understanding, and 
decision-making ability, which might hinder the fight against 2019-nCoV, but could also have a 
lasting effect on their overall wellbeing. Protecting the mental health of these medical workers is 
thus important for control of the epidemic and their own long-term health.” 
“Given more than 80% of patients are confirmed in Hubei province, the hospitals and medical 
workers in Hubei are facing and bearing enormous pressure and severe challenge, including a high 
risk of infection and inadequate protection, as well as overwork, frustration and exhaustion.” 
 
19) Mental health services for older adults in China during the COVID-19 outbreak. 
         Yang Y., et al. The Lancet, 18. 2. 2020. 
“In addition, in most areas of China, clinically stable older adults with psychiatric disorders or their 
guardians usually need to visit psychiatric outpatient clinics monthly to obtain the maintenance 
medications. The current mass quarantines and restrictions to public transport have inevitably 





20) Immediate Psychological Responses and Associated Factors during the Initial Stage of the 
2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China.  
     Wang C., et al. MDPI, 6. 3. 2020. 
“Our findings suggest that with respect to the initial psychological responses of the general public 
from 31 January to 2 February 2020, just two weeks into the country’s outbreak of COVID-19 and 
one day after WHO declared public health emergency of international concern, 53.8% of 
respondents rated the psychological impact of outbreak as moderate or severe.” 
 
21) 2019-nCoV epidemic: address mental health care to empower society. 
        Bao Y., et al. The Lancet, 7. 2. 2020. 
“The challenges and stress they experience could trigger common mental disorders, including 
anxiety and depressive disorders, and posttraumatic stress disorder, which in turn could result in 
hazards that exceed the consequences of the 2019-nCoV epidemic itself.” 
 
22) Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to 
Coronavirus Disease 2019.  
     Lai J., et al. Jama Network Open, 23. 3. 2020. 
“Health care workers responding to the spread of COVID-19 reported high rates of symptoms of 
depression, anxiety, insomnia, and distress. Protecting health care workers is an important 
component of public health measures for addressing the COVID-19 epidemic. Special interventions 
to promote mental well-being in health care workers exposed to COVID-19 need to be immediately 
implemented, with women, nurses, and frontline workers requiring particular attention.” 
 
23) Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 
epidemic in China: a web-based cross-sectional survey.  
         Huang Y., et al. MedRxiv, 9. 3. 2020 
“Our study identified a major mental health burden of the public during COVID-19 epidemic in 
China.” 
“As mental health and public health professionals, we call for adequate and necessary attention to 











24) Patients with mental health disorders in the COVID-19 epidemic.  
          Yao H., et al. ScienceDirect, 19. 3. 2020 
 “Third, the COVID-19 epidemic has caused a parallel epidemic of fear, anxiety, and depression. 
People with mental health conditions could be more substantially influenced by the emotional 
responses brought on by the COVID-19 epidemic, resulting in relapses or worsening of an already 
existing mental health condition because of high susceptibility to stress compared with the general 
population.” 
“Few voices of this large but vulnerable population of people with mental health disorders have 
been heard during this epidemic. Epidemics never affect all populations equally and inequalities 
can always drive the spread of infections.” 
“As mental health and public health professionals, we call for adequate and necessary attention to 
people with mental health disorders in the COVID-19 epidemic.” 
 
25) Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: 
experts’ consensus statement.  
     Shen K., et al. Springer Link, 7. 2. 2020. 
“Psychological counseling plays an important role in disease recovery.” 
 
26) Mental health care for medical staff in China during the COVID-19 outbreak. 
          Chen Q., et al. The Lancet, 18. 2. 2020. 
“The Second Xiangya Hospital, and the Institute of Mental Health, the Medical Psychology 
Research Center of the Second Xiangya Hospital, and the Chinese Medical and Psychological 
Disease Clinical Medicine Research Center responded rapidly to the psychological pressures on 
staff.” 
 
27) COVID-19 and the consequences of isolating the elderly. 
         Armitage R., et al. The Lancet, 19. 3. 2020.  
“If health ministers instruct elderly people to remain home, have groceries and vital 
medications delivered, and avoid social contact with family and friends, urgent action is 
needed to mitigate the mental and physical health consequences.” 
 
28) Preparing for COVID-19: early experience from an intensive care unit in Singapore.  
     Liew F. M., et al. BMC (part of Springer Nature), 9. 3. 2020.  
“Lastly, we realized staff morale took an early hit due to multiple factors, including increased 
workload due to implementation of strict infection control measures, uncertainty over the 
effectiveness of personal protective equipment, anxiety over the lethality of any infection, concern for 






29) Psychological Effects of Quarantine: A Qualitative “Rapid Review”.  
        Roy-Byrne P. NEJM Journal Watch, 26. 2. 2020. 
“The five studies with nonquarantined control groups confirmed distressing impacts on both 
ordinary people and healthcare workers, including anxiety, depression, anger, irritability, and post-
traumatic stress disorder (PTSD).” 
 
30) The psychological impact of quarantine and how to reduce it: rapid review of the evidence.  
     S. K., et al. The Lancet, 14. 3. 2020. 
“Overall, this Review suggests that the psychological impact of quarantine is wide-ranging, 
substantial, and can be long lasting.” 
“Review suggest there can be long-term consequences that affect not just the people quarantined 
but also the health-care system that administered the quarantine and the politicians and public 
health officials who mandated it.” 
 
